Skip to main content
OpenTrials
Completed

NCT Number: NCT00566423

Biomarkers in the Diagnosis and Assessment of Pulmonary Arterial Hypertension (PAH)

The investigators hypothesize that baseline plasma brain natriuretic peptide (BNP) and migration inhibitory factor (MIF) levels are surrogate markers of clinical severity of PAH and that changes in plasma brain natriuretic peptide (BNP) and MIF levels pre and post exercise.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pulmonary Arterial Hypertension Hypertension, Pulmonary Lung Diseases Respiratory Tract Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

North Shore-Long Island Health System

New Hyde Park, New York, 11040, United States

About this study

As above

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Confirmed diagnosis of PAH, based on currently accepted gold standard for Right Heart Catheterization.
  • Patients with mean artery pressure of greater that 25 mm Hg at rest or 30mm Hg during exercise with pulmonary capillary wedge pressure less than 18mm Hg on right heart catheterization.

Exclusion criteria

  • Significant left heart disease or renal insufficiency (serum creatinine > 1.5 mg%).

Treatment and study plan

Blood Draw

Other

Venous and Arterial Blood draw samples; 6 Minute Walk test

Primary outcomes

  1. Assess the correlation of plasma/arterial BNP and MIF levels pre/post with the 6 Minute walk test distance and echocardiographic parameters as surrogate markers of severity of PAH.

    Time frame: 2 year

Secondary outcomes

  1. To determine if changes in plasma/arterial MIF levels pre/post 6MW test are due to MIF released from the lungs

    Time frame: 2 year

Sponsors and collaborators

Lead sponsor

Northwell Health

Other

Registry information

Official study title

Biomarkers in the Diagnosis and Assessment of PAH

Acronym: Biomarkers

Important dates

Study start
2007
Primary completion
2008
Study completion
2010
First posted
Dec 3, 2007
Registry last updated
Jun 23, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.